Welcome to a seminar about:

Advanced Therapy Medicinal Products (ATMPs) in Cancer Care





Preliminary program	
Time	Program
9.00	Karolinska Center for Cell therapy (KCC) and Center for Clinical Cancer studies (CKC): who are we and what do we do? Pontus Blomberg, Head KCC and Stephan Mielke, Director CKC
9.15	ATMPs for treatment of cancer - Karolinskas CAST as a Clinical platform for gene-and cell therapy Stephan Mielke, Scientific Director of the Cancer Center and Head of the Center of Allogeneic Stem Cell Transplantation and Cellular Therapy (CAST) (Karolinska University Hospital)
10.00	Coffee and mingle
10.15	RNA-vaccine as gene therapy against solid tumors Jeffrey Yachnin, Head of phase I unit at Tema Cancer (Karolinska University Hospital)
10.45	Cell therapy against malignant melanoma at Karolinska University Hospital Stina Wickström (Karolinska University Hospital)
11.15	National initiatives to facilitate clinical implementation of ATMPs: Center for Advanced Medical Products (CAMP) and SWElife-ATMP Kristina Kannisto, Project leader KCC and SWElife-ATMP
11.30	End of program




Karolinska Cell Therapy Center (KCC)

Support for development of quality assured Advanced Therapy Medicinal Products (ATMP) and cells for transplantation.




What is KCC?



The purpose of KCC is:

- To provide expertise in Good Manufacturing Practice (GMP) for ATMPs
- To provide support/contact for researchers, clinicians or companies developing ATMPs
- To provide support for medically responsible managers (Verksamhetschefer/POC etc)
- To compile knowledge and know-how, and make it available
- To be a hub in national networks and projects





We are supported by:

- KI/SLL (core facility)
- VINNOVA/Swelife
- Stiftelsen f
 ör Strategisk Forskning (SSF)
- EU-grants
- AFA insurance
- Strategiska Forskningsområden (SFO)
- User fees and other research grants





www.karolinska.se/kcc

Or get in touch:

kcc.karolinska@sll.se

